EP2011504A1 - Produit dermatologique destiné au traitement et/ou au soin de la peau en cas de neurodermatite - Google Patents
Produit dermatologique destiné au traitement et/ou au soin de la peau en cas de neurodermatite Download PDFInfo
- Publication number
- EP2011504A1 EP2011504A1 EP08011814A EP08011814A EP2011504A1 EP 2011504 A1 EP2011504 A1 EP 2011504A1 EP 08011814 A EP08011814 A EP 08011814A EP 08011814 A EP08011814 A EP 08011814A EP 2011504 A1 EP2011504 A1 EP 2011504A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- silver particles
- skin
- treatment
- atopic dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 201000009053 Neurodermatitis Diseases 0.000 title abstract description 6
- 238000004140 cleaning Methods 0.000 title 1
- 239000002884 skin cream Substances 0.000 title 1
- 239000002245 particle Substances 0.000 claims abstract description 81
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229910052709 silver Inorganic materials 0.000 claims abstract description 58
- 239000004332 silver Substances 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 235000008524 evening primrose extract Nutrition 0.000 claims abstract description 28
- 239000010475 evening primrose oil Substances 0.000 claims abstract description 28
- 229940089020 evening primrose oil Drugs 0.000 claims abstract description 28
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 50
- 201000008937 atopic dermatitis Diseases 0.000 claims description 50
- 201000004624 Dermatitis Diseases 0.000 claims description 39
- 239000006210 lotion Substances 0.000 claims description 22
- 206010013786 Dry skin Diseases 0.000 claims description 21
- 230000037336 dry skin Effects 0.000 claims description 21
- 206010015150 Erythema Diseases 0.000 claims description 18
- 206010003645 Atopy Diseases 0.000 claims description 17
- 208000003251 Pruritus Diseases 0.000 claims description 15
- 230000007803 itching Effects 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 9
- 231100000321 erythema Toxicity 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 206010030113 Oedema Diseases 0.000 claims description 6
- 206010033733 Papule Diseases 0.000 claims description 6
- 206010048222 Xerosis Diseases 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 2
- 208000010340 Sleep Deprivation Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 230000001139 anti-pruritic effect Effects 0.000 abstract 1
- 239000003908 antipruritic agent Substances 0.000 abstract 1
- 230000000147 hypnotic effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 description 40
- 210000003491 skin Anatomy 0.000 description 35
- 230000008859 change Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 208000035874 Excoriation Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000007717 exclusion Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 206010024438 Lichenification Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 4
- 229960004544 cortisone Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000005722 itchiness Effects 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 235000004433 Simmondsia californica Nutrition 0.000 description 3
- 244000044822 Simmondsia californica Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 229940074979 cetyl palmitate Drugs 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 3
- 229940049290 hydrogenated coco-glycerides Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940126602 investigational medicinal product Drugs 0.000 description 3
- 230000008807 pathological lesion Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- 241000183672 Echium plantagineum Species 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- -1 alkyl benzoates Chemical class 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- CBFCDTFDPHXCNY-UHFFFAOYSA-N icosane Chemical compound CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- LEIXEEFBKOMCEQ-AFJQJTPPSA-N (9z,12z)-heptadeca-9,12-dienoic acid Chemical compound CCCC\C=C/C\C=C/CCCCCCCC(O)=O LEIXEEFBKOMCEQ-AFJQJTPPSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000871261 Cardiospermum Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001071905 Echium Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000003079 shale oil Substances 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Definitions
- the invention relates to the use of silver particles having a mean particle size of 1 to 100 microns for the care of dry skin, especially neurodermitic skin conditions and for the treatment of atopic dermatitis and a composition comprising these silver particles and evening primrose oil and the use of such a composition as a skin care agent, especially in dry skin as well as neurodermitic skin conditions, and for the treatment of atopic dermatitis.
- Dry skin looks rough, shiny or cracked, sometimes red or flaky. Dry skin can form or increase wrinkles. Dry skin is not just a cosmetic problem, because dry skin can be sensitive, tense and itchy. In addition, dry skin tends to inflammation and may favor the development of eczema.
- Dry skin can be systemic, often occurs in the elderly, where the epidermis is no longer producing enough lipid, and can be the result of excessive care, dry air, and chronic UV damage.
- W / O emulsions are usually used, which are to provide the skin with moisture and fat and stabilize the horny layer barrier.
- Such care agents have no alcohol.
- Atopic dermatitis is a skin disease whose main symptoms are red, flaky, possibly also weeping eczema on the skin and an often tormenting itching. Other common names for eczema include atopic dermatitis, atopic dermatitis and endogenous eczema. Atopic dermatitis is a chronic inflammatory reaction of the skin.
- Atopic dermatitis often occurs for the first time in toddlers, but adolescents and adults can also develop eczema for the first time.
- the symptoms of the disease may be different in different individuals and on different skin areas.
- the atopic dermatitis can occur in bouts of different duration and strength.
- atopic dermatitis manifests itself symptomatically, especially in a very sensitive and dry skin, which is often also red.
- a skin problem is often a strong itching sensation to the affected person. Scratching the skin can cause it to crack, which can lead to eczema, which often wets and aggravates the itching.
- the most common skin areas affected by atopic dermatitis are the armpits, the popliteal fossae, and the neck and facial areas.
- cortisone In the prior art many ways of treating atopic dermatitis are known, which in addition to drug therapies and the prevention of certain foods and external stimuli or stress counts.
- a drug therapy eczema is often treated by cortisone.
- oral administration of cortisone-containing drugs may also be considered.
- the disadvantage of cortisone treatment is that it can often only be used for a short time in cases of acute episodes of atopic dermatitis and results in skin thinning, strong hairiness, stretch marks and partial suppression of the local immune system. With prolonged use of cortisone preparations also systemic damage to the organism may occur, such. As liver damage or inducing glaucoma. But other drug therapies, such.
- This object is achieved by using silver particles of an average particle size of 1 .mu.m to 100 .mu.m in combination with evening primrose oil as dermatics in dry skin, especially neurodermitic skin conditions.
- silver particles having an average particle size of 1 to 100 ⁇ m are used for the treatment of atopic dermatitis or for the production of a medicament for the treatment of atopic dermatitis.
- microsilver In the prior art, the antimicrobial action of metallic silver is well known.
- silver particles of a size of 1 .mu.m to 100 .mu.m so-called microsilver or microsilver are now used for the treatment of atopic dermatitis.
- silver particles having an average particle size of from 1 ⁇ m to 100 ⁇ m have a positive influence on the symptoms occurring under the clinical picture of atopic dermatitis, such as edema / papule formation, Redness / erythema formation, crusting, excoriation, lichenification, increased itching, dryness (xerosis), scaling and lack of sleep have.
- Colloidal silver is known in the art. Colloidal silver consists of electrically charged silver particles in water. The particle size of silver in colloidal silver is between 1 and 10 nm. With topical application of this colloidal silver, the silver particles can penetrate into deeper skin layers. The effects of silver nanoparticles on human health when they have invaded the body are not yet known. However, it is known that nanoscale silver, so-called colloidal silver, can deposit in the body at too high a concentration and can lead to so-called silver deposits.
- the silver particles used according to the invention of a size of 1 ⁇ m to 100 ⁇ m do not have the disadvantages associated with the use of silver nanoparticles of a size of 1 to 100 nm.
- the silver particles used in the invention are so large that they can not penetrate into the human body when applied topically. They can not be absorbed into the body via the bloodstream.
- the silver particles according to the present invention have an average particle size of 1 .mu.m to 100 .mu.m, preferably 2 .mu.m to 20 .mu.m and more preferably 2 .mu.m to 5 .mu.m. It is prepared by methods known in the art.
- the silver particles according to the invention are preferably made of pure silver. But you can also contain in a small proportion of up to 1 wt .-% other metals, such as. As zinc and / or copper. Particularly advantageously, the silver particles impurities of less than 5 ppm, more preferably they are made of pure silver. Possible impurities of the silver particles may, for. As potassium, sodium or chlorine.
- the silver particles are present in an average particle size of 1 .mu.m to 100 .mu.m as porous particles.
- the mean inner porosity of the silver particles can be z. B. at least 65%, in particular 65 to 95%. Particularly preferred is an average internal porosity of 85% to 95%.
- the porosity of the particles can be determined according to the in WO 2005/023213 on page 7.
- the silver particles used are present as agglomerates of metallic primary particles whose average particle diameter is between 10 and 200 nm, preferably between 15 and 80 nm.
- Such porous silver particles may according to the in WO 2005/023213 described processes, in particular that on page 10 of WO 2005/023213 described method.
- Such silver particles having an average particle diameter of 1 .mu.m to 100 .mu.m, which have an inner porosity, are z. B. from the company Biogate available.
- a combination of the described silver particles having an average particle size of 1 to 100 ⁇ m and evening primrose oil is used for the treatment of atopic dermatitis or for the production of a medicament for the treatment of atopic dermatitis.
- the treatment of atopic dermatitis both with silver particles of an average particle size of 1 to 100 microns as well as a combination of these silver particles and evening primrose oil can be both a pharmaceutical and a cosmetic and is carried out by topical application of the silver particles, optionally in combination with evening primrose oil to that of atopic dermatitis affected skin.
- Another object of the present invention are stable compositions comprising the described silver particles having an average particle size of 1 to 100 microns and evening primrose oil.
- evening primrose oil contains a large amount of unsaturated fatty acids, especially a high proportion of cis-linoleic acid. It is thus very susceptible to spoilage, particularly oxidative spoilage, which is accelerated by the presence of catalytically active metals in compositions containing evening primrose oil.
- compositions according to the invention has a positive effect in the treatment of dry skin, in particular neurodermitic skin conditions and atopic dermatitis.
- use of the described silver particles having an average particle size of 1 to 100 .mu.m and evening primrose oil the symptoms of edema / papule formation, reddening / erythema formation, encrustation, excoriation, lichenification, increased itching occurring under the clinical picture of atopic dermatitis , Reduce dryness (xerosis), scaling and lack of sleep or disappear.
- compositions or remedies according to the invention containing the described silver particles and aftercandy oil are in the form of an O / W emulsion, in particular as an alcoholic O / W emulsion.
- Dry skin care agents known in the art and agents for the treatment of atopic dermatitis are formulated as a W / O emulsion so that the oil phase is in direct skin contact.
- the known in the prior art care products for dry skin especially neurodermitic skin conditions, as well as the cure for the treatment of atopic dermatitis alcohol-free, since alcohol dehydrates the skin affected by atopic dermatitis.
- compositions of the invention which have an O / W galenics, the alcohol contained therein not to another Dehydration of the skin or aggravation of the symptoms occurring at the onset of atopic dermatitis leads, but in addition to the microbiological effect has a pleasant cooling effect and is completely tolerated by the skin.
- the compositions of the invention are characterized according to a preferred embodiment by an alcohol content of at least 1 wt .-%, in particular 5-15 wt .-% of.
- compositions according to the invention are characterized in that they are free from PEG emulsifiers, that is to say emulsifiers based on polyethylene glycol, free from preservatives and free from perfumes.
- compositions according to the invention are formulated as stable silver particle formulations, for example as lotion, paste, ointment, cream, emulsion, gel, powder or suspension.
- Stable means that the formulation is stable on storage, that is, the silver particles do not sediment during storage and optionally contained evening primrose oil is not decomposed silver-catalytically.
- the silver particles are present in the compositions according to the invention in amounts of from 0.001% by weight to 10% by weight, preferably from 0.01% by weight to 5% by weight and more preferably from 0.1% by weight Wt .-% and in particular 0.1 wt .-% - 0.5 wt .-% before and are also used according to the claimed use preferably in these ranges.
- the evening primrose oil is present in the compositions according to the invention in amounts of from 0.1% by weight to 30% by weight, particularly preferably from 1% by weight to 10% by weight, and according to the further claimed use, it is likewise preferred in this composition Quantity range applied.
- Applicant's study in a study of various compositions comprising silver particles having a mean particle size of 1 to 100 microns and evening primrose oil have a highly significant reduction in the atopic dermatitis associated disorders such as edema / papule formation, redness / erythema formation, crust formation, Excoriation, lichenification, increased itching, dryness (xerosis) and lack of sleep. It has been found that topical application of a composition comprising silver particles having an average particle size of 1 to 100 microns and evening primrose oil lowers the atopy index of atopic dermatitis subjects to topical application of this composition and in many cases even eliminates the neurodermatitis problems.
- Example 1 Example 2
- Example 3 Example 4
- Example 5 Polyglyceryl-3-methylglucose distearate 4.00 4.0 4.2 3.8 4.2 Hydrogenated Coco-Glycerides 1.00 1.00 0.8 1.1 0.8 Cetyl palmitate 1.00 0.9 0.8 1.2 0.9 Cetyl Alcohol 3.00 2.5 2.5 3.2 3 C12-15 alkyl benzoates 8.00 7.8 7.8 8.5 8.2 Simmondsia Chinensis Seed Oil 6.00 5.5 5.5 6 6 isopropyl myristate 5.00 4.5 4.5 5 5 Octyldodecanol, Echium Plantagineum, Cardiospermum, Halicacabum, Helianthus annuus 2.00 1 1 0 0 Evening primrose oil 6.00 4.00 2.00 8.00 5.00 Tocopheryl acetate 1.00 0.8 1.2 1.2 1 MicroSilver 0.30 0.32 0.5 0.25 0.1 Aqua 46,40 53.9 62.14 45.91 55.28 Xanthan gum 0.30 0.28 0.
- phase I consisting of polyglyceryl-3-methylglucose distearate, hydrogenated coco-glycerides, cetyl palmitate, cetyl alcohol, C12-15 Alkyl Benzoate, Simmondsia Chinensis seed oil, isopropyl myristate, evening primrose oil, tocopheryl acetate and microsilver, and optionally Octyldodecanol, Echium Plantagineum, Cardiospermnum, Halicacabum and Helianthus Annuus, while stirring the heated to 75 ° C phase II, consisting of Aqua, xanthan gum, glycerol and optionally butylene glycol.
- phase II consisting of Aqua, xanthan gum, glycerol and optionally butylene glycol.
- the composition is further homogenized, then cooled to 45 ° C and optionally Alcohol Denat added. After further homogenization, the mass is finally cooled with stirring to room temperature.
- Example 6 Weighing [g / 100g]
- Example 7 Weighing [g / 100g]
- Example 8 Weighing [g / 100g]
- Example 9 Weighing [g / 100g]
- Example 10 Weighing [g / 100g] Polyglyceryl-3-methylglucose distearate 3.00 3.00 3.2 2.8 2.8 Hydrogenated Coco-Glycerides 0.75 0.75 0.7 0.8 0.8 Cetyl palmitate 0.75 0.75 0.9 0.8 0.7 Cetyl Alcohol 2.25 2.25 2.5 2.2 2.0 C12-15 alkyl benzoates 8.00 8.00 7.8 8.5 8.2 Simmondsia Chinensis Seed Oil 6.00 6.00 4.00 7.00 5.00 isopropyl myristate 5.00 5.00 5.5 5.2 4.8 Octyldodecane, Echium palntagineum, Cardiospernum, Halicacabum, Helianthus, Annus 2.00 2.00 2.5 1 0 Evening primrose oil 6.00 6.00 4.00 2.00 8
- Table 1 Subjects of the subject collective A number gender Age diagnosis application site 1 w eczema Arms legs 2 w 42 eczema Arms, backs of hands 3 w 50 eczema Arms legs 4 w 44 eczema Arms legs 5 w 47 eczema Arms legs 6 w 18 eczema Arms legs 7 w 44 eczema Forehead, arms 8th w 42 eczema Arms, backs of hands 9 m 43 eczema legs 10 m 40 eczema Arms, backs of hands 11 m 46 eczema poor 12 w 28 eczema poor 13 w 38 eczema Arms, backs of hands 14 w 36 eczema Arms, backs of hands 15 w 66 eczema Arms, backs of hands
- Subjects of the subject group B number gender Age diagnosis application site 1 w 34 eczema Face, arms and legs 2 w 20 eczema poor 3 w 19 eczema Arms, backs of hands 4 w 45 eczema Arms legs 5 m 34 eczema Arms, backs of hands 6 w 55 eczema poor 7 w 50 eczema Arms legs 8th w 19 eczema Arms legs 9 w 34 eczema Arms legs 10 w 39 eczema Arms, legs, backs of hands 11 w 49 eczema Arms legs 12 w 46 eczema Arms legs 13 m 35 eczema Face, arms, legs 14 w 44 eczema Arms legs 15 w 36 eczema legs
- the subjects of the groups A and B were given the product cream according to example 1 as well as the subject diaries with the Application instruction given at least twice a day. Furthermore, the subjects were asked to refrain from other preparations in the testarial during the application test.
- the maximum total value as a modified SCORAD is 50, as an expression of a mean expression of the atopic disease. Calculation of the index: 7A / 2 + B / 5 + C.
- the evaluation of the subjective assessment criteria was carried out by the subjects as part of the daily documentation in the subject diary.
- Tables 3-7 summarize the evaluations of the subjective assessment criteria of the subject diaries of the subject collective A, which were prepared after a 10-day application of the cream according to Example 1 in the 18-day period of application of the lotion according to Example 2 from day 11 to day 28.
- Table 3 gives the subjectively assessed severity of the skin disease.
- Table 4 shows the subjectively assessed erythema of the skin.
- Table 5 shows the subjectively assessed dryness of the skin.
- Table 6 shows the subjectively assessed itching.
- Table 7 shows the subjectively assessed effect of the investigational medicinal product (here the lotion according to Example 2).
- Tables 8-12 summarize the evaluations of the subjective assessment criteria of the subject diaries of the subject group B, which was prepared after a 10-day application of the cream according to Example 1 in 18-day period of application of the lotion according to Example 3 from day 11 to day 28.
- Table 8 gives the subjectively assessed severity of the skin disease.
- Table 9 shows the subjectively assessed redness.
- Table 10 shows the subjectively assessed dryness.
- Table 11 shows the subjectively assessed itching.
- Table 12 shows the subjectively assessed effect of the investigational medicinal product (here the lotion according to Example 3).
- Table 13 shows the atopy score of subject group A before application of the lotion of Example 6 on day 11 of the study ("input value”) and after 18 days Application of the lotion according to Example 6 on day 28 of the study ("after 18 days”) and the corresponding absolute and percentage change indicated.
- the average atopy value decreased from 27.14 to 6.39. This corresponds to a reduction of - 76.44% from baseline.
- Table 14 shows the atopy score of subject group B before application of the lotion according to Example 7 on day 11 of the study ("input value") and after 18 days application of the lotion according to example 7 on day 28 of the study ("after 18 days”). ) and the corresponding absolute and percentage change.
- the average atopy value decreased from 19.11 to 6.99. This corresponds to a reduction of - 63.45% from baseline.
- Table 15 shows the atopy score of subjects A (subjects 1-15) and B (subjects 16-30) before the start of the study ("input value") and at the end of the study, ie after 10 days of application of the cream according to example 1 and 18 daily application of the lotion according to Example 6 in the subject group A or the lotion according to Example 7 in the subject group B reproduced.
- the index for atopy has decreased values:
- the atopy score decreases on average by 82.59%.
- Another object of the present invention is therefore the use of a composition comprising the described silver particles having an average particle size of 1-100 microns and evening primrose oil, in particular present as alcoholic O / W emulsion, for reducing the average atopy score, especially at 18 or 28-day use, by at least 40%, preferably 60%, more preferably 70% and in particular 80%.
- Table 3 Subject group A, severity of the skin disease, application of lotion according to Example 6 Another 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 No.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007031650A DE102007031650A1 (de) | 2007-07-06 | 2007-07-06 | Dermatikum zur Behandlung und/oder Pflege der Haut bei Neurodermitis |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2011504A1 true EP2011504A1 (fr) | 2009-01-07 |
EP2011504B1 EP2011504B1 (fr) | 2011-12-28 |
Family
ID=39798230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08011814A Active EP2011504B1 (fr) | 2007-07-06 | 2008-07-01 | Produit dermatologique destiné au traitement et/ou au soin de la peau en cas de neurodermatite |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2011504B1 (fr) |
AT (1) | ATE538803T1 (fr) |
DE (1) | DE102007031650A1 (fr) |
ES (1) | ES2379474T3 (fr) |
PT (1) | PT2011504E (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202011003362U1 (de) | 2011-03-01 | 2011-06-01 | Dr. Theiss Naturwaren GmbH, 66424 | Zusammensetzung, insbesondere dermatologische Salbe |
WO2017093508A1 (fr) * | 2015-12-02 | 2017-06-08 | Wild & Natural Ibiza Cosmetics Corp. S.L. | Composition pour le soin de la peau |
WO2020245569A1 (fr) * | 2019-06-06 | 2020-12-10 | Boston Healthcare Limited | Composition de traitement de la peau |
EP3977858A1 (fr) * | 2020-10-01 | 2022-04-06 | Hans Karrer GmbH | Crème pour les mains antivirale désinfectante |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030180378A1 (en) | 2000-07-27 | 2003-09-25 | Gillis Scott H. | Dry powders of metal-containing compounds |
WO2005023213A1 (fr) | 2003-08-29 | 2005-03-17 | Bio-Gate Ag | Produit de soin corporel contenant des particules poreuses d'argent |
EP1520577A1 (fr) | 2003-09-30 | 2005-04-06 | Kneipp-Werke Kneipp-Mittel-Zentrale GmbH & CO. KG | Composition cosmétique ou dermatologique comprenant l'huile d'onagre |
DE102004016129A1 (de) | 2004-03-31 | 2005-10-20 | Bitop Ag | Topische Zubereitung zur Anwendung auf der Haut enthaltend natürliches Öl der Nachtkerze (Oenothera biennis) (=Oleum Oenotherae) und Osmolyte aus extremophilen Mikroorganismen |
US20050271743A1 (en) | 2001-04-23 | 2005-12-08 | Burrell Robert E | Treatment of inflammatory skin conditions |
DE102005008299A1 (de) | 2005-02-23 | 2006-12-28 | Icb Investment Consulting Beteiligungen Gmbh | Universalpflegecreme |
-
2007
- 2007-07-06 DE DE102007031650A patent/DE102007031650A1/de not_active Withdrawn
-
2008
- 2008-07-01 PT PT08011814T patent/PT2011504E/pt unknown
- 2008-07-01 AT AT08011814T patent/ATE538803T1/de active
- 2008-07-01 ES ES08011814T patent/ES2379474T3/es active Active
- 2008-07-01 EP EP08011814A patent/EP2011504B1/fr active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030180378A1 (en) | 2000-07-27 | 2003-09-25 | Gillis Scott H. | Dry powders of metal-containing compounds |
US20050271743A1 (en) | 2001-04-23 | 2005-12-08 | Burrell Robert E | Treatment of inflammatory skin conditions |
WO2005023213A1 (fr) | 2003-08-29 | 2005-03-17 | Bio-Gate Ag | Produit de soin corporel contenant des particules poreuses d'argent |
EP1520577A1 (fr) | 2003-09-30 | 2005-04-06 | Kneipp-Werke Kneipp-Mittel-Zentrale GmbH & CO. KG | Composition cosmétique ou dermatologique comprenant l'huile d'onagre |
DE102004016129A1 (de) | 2004-03-31 | 2005-10-20 | Bitop Ag | Topische Zubereitung zur Anwendung auf der Haut enthaltend natürliches Öl der Nachtkerze (Oenothera biennis) (=Oleum Oenotherae) und Osmolyte aus extremophilen Mikroorganismen |
DE102005008299A1 (de) | 2005-02-23 | 2006-12-28 | Icb Investment Consulting Beteiligungen Gmbh | Universalpflegecreme |
Non-Patent Citations (3)
Title |
---|
HOLTMANN U: "Drug products made from Oenothera biennis oil = Nachtkerzenöl-haltige Produkte. GLS ist nicht gleich GLS", 1 January 1996, TW PAEDIATRIE, KARLSRUHE, DE, PAGE(S) 309,311, ISSN: 0935-3216, XP009107007 * |
RING J ET AL: "Evening primrose oil in neurodermatitis? = Nachtkerzenöl bei Neurodermitis?", 1 September 1991, MEDIZINISCHE MONATSSCHRIFT FUER PHARMAZEUTEN, STUTTGART, DE, PAGE(S) 282, ISSN: 0342-9601, XP009107008 * |
SWARNA EKANAYAKE-MUDIYANSELAGE ET AL: "Anwendungsbeobachtung mit einem topischen silberhaltigen Pflegeprodukt (Multilind TM MikroSilber Creme) zur Überprüfung der Wirksamkeit, Verträglichkeit und kosmetischen Akzeptanz beim atopischen Ekzem", 1 January 2007, KOSMETISCHE MEDIZIN, GROSSE VERLAG GMBH, BERLIN, DE, PAGE(S) 291 - 295, ISSN: 1430-4031, XP009106957 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202011003362U1 (de) | 2011-03-01 | 2011-06-01 | Dr. Theiss Naturwaren GmbH, 66424 | Zusammensetzung, insbesondere dermatologische Salbe |
EP2494968A1 (fr) | 2011-03-01 | 2012-09-05 | Dr. Theiss Naturwaren GmbH | Composition, notamment pommade dermatologique avec de l'huile des fruits d'Olea Europaea et de l'argent |
WO2017093508A1 (fr) * | 2015-12-02 | 2017-06-08 | Wild & Natural Ibiza Cosmetics Corp. S.L. | Composition pour le soin de la peau |
WO2020245569A1 (fr) * | 2019-06-06 | 2020-12-10 | Boston Healthcare Limited | Composition de traitement de la peau |
EP3977858A1 (fr) * | 2020-10-01 | 2022-04-06 | Hans Karrer GmbH | Crème pour les mains antivirale désinfectante |
Also Published As
Publication number | Publication date |
---|---|
ES2379474T3 (es) | 2012-04-26 |
EP2011504B1 (fr) | 2011-12-28 |
ATE538803T1 (de) | 2012-01-15 |
PT2011504E (pt) | 2012-04-10 |
DE102007031650A1 (de) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4593046A (en) | Method of reducing skin irritation from benzoyl peroxide | |
Syed et al. | Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo‐controlled, double‐blind study | |
EP2504012B1 (fr) | Utilisation d'un oléogel contenant du triterpène pour la cicatrisation de plaies | |
EP1755630B1 (fr) | Compositions pharmaceutiques contenant de l'usnee barbata et et de l'hypericum perforatum, et leur utilisation | |
EP2494968A1 (fr) | Composition, notamment pommade dermatologique avec de l'huile des fruits d'Olea Europaea et de l'argent | |
EP2011504B1 (fr) | Produit dermatologique destiné au traitement et/ou au soin de la peau en cas de neurodermatite | |
Nong et al. | A review of the use of beeswax in skincare | |
DE60133038T2 (de) | Hypoallergenisches nichtreizendes hautpflegemittel | |
EP3492089B1 (fr) | Composition dermatologique contenant escherichia coli et enterococcus faecalis | |
EP0691126A1 (fr) | Compositions cosmétiques ou dermatologiques contenant alpha-hydroxy acides et/ou acides cétoniques et pigments inorganiques | |
DE102005008299A1 (de) | Universalpflegecreme | |
WO2000030660A2 (fr) | Hyperforine s'utilisant comme cytostatique et pommade ou creme a base d'hyperforine comme forme galenique d'application | |
DE3443242A1 (de) | Glycyrrhizin und einen wirkstoff enthaltendes arzneimittel | |
WO2023104843A1 (fr) | Préparation pour application topique pour améliorer l'état de la peau | |
DE3315463A1 (de) | Arzneimittel zur lokalen behandlung von psoriasis | |
DE60212842T2 (de) | Dermatologische zusammensetzungen, die nikotinsäure oder nikotinsäureamid und sphingoid-base enthalten | |
CN114306106B (zh) | 皮肤用组合物及其用途 | |
EP2620146A1 (fr) | Iibuprofène pour le traitement de kératose actinique | |
EP2399648B1 (fr) | Composition cosmétique et son utilisation | |
EP2120953B1 (fr) | Composition pour le traitement topique de maladies cutanées | |
CN114306107A (zh) | 功效型皮肤用产品及其制备方法 | |
DE202007004981U1 (de) | Zusammensetzung, insbesondere für die topische Behandlung von Hauterkrankungen | |
EP1131101B1 (fr) | Preparation de khelline et son utilisation pour des traitements a action locale | |
CN113995701B (zh) | 一种祛痘和消除痘印的组合物及其制备方法和应用 | |
EP3909563B1 (fr) | Crème cosmétique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
17P | Request for examination filed |
Effective date: 20090605 |
|
17Q | First examination report despatched |
Effective date: 20090708 |
|
AKX | Designation fees paid |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 538803 Country of ref document: AT Kind code of ref document: T Effective date: 20120115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 502008005971 Country of ref document: DE Effective date: 20120322 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20120326 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2379474 Country of ref document: ES Kind code of ref document: T3 Effective date: 20120426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120328 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20111228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120329 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 11325 Country of ref document: SK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120328 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120428 Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 |
|
26N | No opposition filed |
Effective date: 20121001 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 502008005971 Country of ref document: DE Effective date: 20121001 |
|
BERE | Be: lapsed |
Owner name: STADA ARZNEIMITTEL A.G. Effective date: 20120731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20120701 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20130329 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120701 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080701 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 502008005971 Country of ref document: DE Representative=s name: HAMM & WITTKOPP PATENTANWAELTE PARTMBB, DE |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230503 |
|
P02 | Opt-out of the competence of the unified patent court (upc) changed |
Effective date: 20230530 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20230620 Year of fee payment: 16 Ref country code: CZ Payment date: 20230629 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20230619 Year of fee payment: 16 Ref country code: NL Payment date: 20230719 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230810 Year of fee payment: 16 Ref country code: AT Payment date: 20230711 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230621 Year of fee payment: 16 |